• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $IMVT

    Immunovant Inc.

    Subscribe to $IMVT
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

    IPO Year: 2019

    Exchange: NASDAQ

    Website: immunovant.com

    Peers

    $XBIO

    Recent Analyst Ratings for Immunovant Inc.

    DatePrice TargetRatingAnalyst
    3/3/2025$20.00Hold
    Jefferies
    1/3/2025Outperform → Peer Perform
    Wolfe Research
    10/10/2024$36.00Outperform
    Raymond James
    10/9/2024$47.00 → $53.00Outperform
    Oppenheimer
    3/28/2024$50.00Outperform
    Oppenheimer
    3/13/2024$50.00Buy
    Goldman
    2/20/2024$51.00Overweight
    JP Morgan
    2/15/2024$55.00Outperform
    Wolfe Research
    12/12/2023$50.00Buy
    Deutsche Bank
    10/13/2023$18.00 → $55.00Neutral → Buy
    UBS
    See more ratings

    Immunovant Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Girao Tiago was granted 208,388 shares (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      5/5/25 7:30:09 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Susman Robert Graham was granted 25,016 shares (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      5/5/25 7:30:05 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Bauer Jake was granted 25,016 shares (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      5/5/25 7:30:07 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Girao Tiago

      3 - Immunovant, Inc. (0001764013) (Issuer)

      4/28/25 5:03:01 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Bauer Jake

      3 - Immunovant, Inc. (0001764013) (Issuer)

      4/28/25 5:02:21 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Susman Robert Graham

      3 - Immunovant, Inc. (0001764013) (Issuer)

      4/28/25 5:01:19 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Technology Officer Stout Jay S sold $28,471 worth of shares (1,925 units at $14.79), decreasing direct ownership by 0.91% to 209,243 units (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      4/25/25 4:17:18 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Geffner Michael sold $34,742 worth of shares (2,349 units at $14.79), decreasing direct ownership by 1% to 225,370 units (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      4/25/25 4:15:56 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Barnett Eva Renee sold $44,566 worth of shares (2,993 units at $14.89), decreasing direct ownership by 0.75% to 396,774 units (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      4/17/25 4:08:29 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Salzmann Peter sold $123,900 worth of shares (8,321 units at $14.89), decreasing direct ownership by 0.70% to 1,178,191 units (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      4/17/25 4:07:30 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Immunovant Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    Immunovant Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Director Roivant Sciences Ltd. bought $336,900,200 worth of shares (16,845,010 units at $20.00), increasing direct ownership by 21% to 96,650,341 units (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      1/15/25 4:36:38 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roivant Sciences Ltd. was granted 4,473,684 shares and bought $58,000,008 worth of shares (1,526,316 units at $38.00), increasing direct ownership by 8% to 79,805,331 units (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      10/4/23 5:15:20 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunovant Inc.

      SC 13G/A - Immunovant, Inc. (0001764013) (Subject)

      11/12/24 10:32:13 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Immunovant Inc. (Amendment)

      SC 13G/A - Immunovant, Inc. (0001764013) (Subject)

      2/14/24 8:47:41 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Immunovant Inc.

      SC 13G - Immunovant, Inc. (0001764013) (Subject)

      2/9/24 9:16:06 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Immunovant Inc. (Amendment)

      SC 13D/A - Immunovant, Inc. (0001764013) (Subject)

      10/4/23 5:19:22 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Immunovant Inc. (Amendment)

      SC 13G/A - Immunovant, Inc. (0001764013) (Subject)

      2/14/23 8:37:51 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Immunovant Inc. (Amendment)

      SC 13G/A - Immunovant, Inc. (0001764013) (Subject)

      12/5/22 4:09:51 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Immunovant Inc. (Amendment)

      SC 13G/A - Immunovant, Inc. (0001764013) (Subject)

      12/2/22 4:06:00 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Immunovant Inc.

      SC 13G - Immunovant, Inc. (0001764013) (Subject)

      2/11/22 5:11:07 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed

      SC 13D/A - Immunovant, Inc. (0001764013) (Subject)

      3/8/21 8:00:45 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Immunovant, Inc. (0001764013) (Subject)

      2/16/21 10:37:36 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Immunovant Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

      Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction)Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70%In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepointsINDs active for both MG and CIDP wi

      3/19/25 7:45:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast DetailsThe company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast

      3/18/25 4:32:00 PM ET
      $IMVT
      $ROIV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast Details The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The l

      3/18/25 4:32:00 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

      Lead asset IMVT-1402 rapidly progressing with now six Investigational New Drug (IND) applications cleared and pivotal studies in Graves' disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) now enrolling with 2.25ml autoinjector Additional results from batoclimab proof-of-concept study in GD, including 6-month treatment free remission data expected in summer 2025 Top line results of the batoclimab trial in myasthenia gravis (MG) and initial results from period 1 of batoclimab trial in chronic inflammatory demyelinating polyneuropathy (CIDP) expected by March 31, 2025 Pro forma cash balance of approximately $825 million as of December 31, 2024, including approximately $450 mil

      2/6/25 6:30:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Announces $450 Million Private Placement

      NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it has agreed to sell an aggregate of 22,500,000 shares of common stock at a purchase price of $20.00 per share to three institutional accredited investors in a private investment in public equity (PIPE). Immunovant anticipates receiving aggregate gross proceeds of approximately $450 million from the PIPE. The PIPE is expected to close on or about January 15, 2025, subject to the satisfaction of customary closing conditions. Immunovant expects to use the proceeds from the PIPE for the adv

      1/13/25 8:00:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

      Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves' disease (GD) demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs (ATDs); initiation of potentially registrational trial to evaluate IMVT-1402 in GD expected by year endIND cleared for IMVT-1402 in rheumatoid arthritis (RA), with potential best-in-class profile in difficult-to-treat (D2T) RA; initiation of potentially registrational trial to evaluate IMVT-1402 in D2T RA expected by March 31, 2025O

      11/7/24 6:30:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

      NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that data from the Phase 2a trial of batoclimab in Graves' disease will be the subject of an oral presentation of a late-breaking abstract accepted for the 2024 American Thyroid Association (ATA) Annual Meeting being held October 30 to November 3, 2024, in Chicago, Illinois. New data highlighting both thyroid-specific and extrathyroidal manifestations of Graves' disease will be presented. Late-Breaking Oral Presentation Details: Title:Efficacy and Safety of the FcRn Inhibitor, Batoc

      10/29/24 6:30:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

      Ankyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors effective September 25, 2024. They will both serve as independent board members and their appointment brings the total board composition to seven directors. "We are delighted to welcome Dr. Butchko and Ms. Withington to the Board", stated Tillman Gerngross, PhD, Chairman of the Ankyra Board of Directors. "These accomplished individuals bring a fresh perspective to Ankyra at a critical time in the company's growth." Howard L. Kaufman, MD, President and Chief Executive Officer at Ankyra added "I am especially enthusiastic about working with Dr. Butchko and Ms. Withington sin

      9/23/24 8:00:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Provides Update on Graves' Disease Development Program

      High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-Free response rate in patients uncontrolled on ATDs at week 12Strong correlation observed between degree of IgG lowering and clinical outcomes yields potential best-in-class and first-in-class opportunity for IMVT-1402 in Graves' Disease (GD)Real world claims data indicates 25-30% of Graves' Disease patients per year are uncontrolled on ATDs with minimal to no existing therapeutic options representing an attractive commercial opportunity with limited competitionIND cleared with initiation of IMVT-1402 pivotal trial in GD expected by calendar yea

      9/9/24 3:55:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant to Host Graves' Disease Program Update on September 9, 2024

      NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Monday, September 9th at 8:00 a.m. ET to provide an update on its Graves' Disease (GD) program. The update will consist of new epidemiologic data characterizing the potentially addressable market, additional results from the Phase 2 study of batoclimab, and an overview of the IMVT-1402 development program in GD. Webcast Details The company will host a webcast at 8:00 a.m. ET on Monday, September 9th. Please click here to register for the event. The

      9/5/24 6:30:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Immunovant Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

      Ankyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors effective September 25, 2024. They will both serve as independent board members and their appointment brings the total board composition to seven directors. "We are delighted to welcome Dr. Butchko and Ms. Withington to the Board", stated Tillman Gerngross, PhD, Chairman of the Ankyra Board of Directors. "These accomplished individuals bring a fresh perspective to Ankyra at a critical time in the company's growth." Howard L. Kaufman, MD, President and Chief Executive Officer at Ankyra added "I am especially enthusiastic about working with Dr. Butchko and Ms. Withington sin

      9/23/24 8:00:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Appoints Mark Levine as Chief Legal Officer

      Mr. Levine adds valuable experience to the leadership team as Immunovant accelerates the development of batoclimab with the expected initiation of three pivotal trials in 2022 NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced the appointment of Mark Levine as Chief Legal Officer. "We are extremely pleased to welcome Mark Levine as Immunovant's Chief Legal Officer," said Pete Salzmann, M.D., Chief Executive Officer. "Mark's broad legal experience at biopharmaceutical companies ranging from early-stage development through commercialization wil

      1/25/22 8:30:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Appoints Renee Barnett as Chief Financial Officer

      Ms. Barnett brings a wealth of financial experience to ImmunovantExpands executive leadership team as Immunovant plans to return to the clinic across multiple indications NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced the appointment of Renee Barnett, as Chief Financial Officer, effective October 4, 2021. "We are incredibly excited to have Renee Barnett join the Immunovant management team at this important time for our company," said Pete Salzmann, M.D., Chief Executive Officer. "Renee brings a deep understanding of drug developmen

      9/15/21 7:00:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Appoints Rita Jain Chief Medical Officer And Provides Corporate Update

      Dr. Jain brings deep expertise in the design and execution of complex clinical trials, having overseen the development of more than 15 new chemical entities and marketed productsDr. Jain’s broad and diverse clinical experience makes her uniquely well-suited to lead the initiation of multiple Phase 3 programs for IMVT-1401 across different therapeutic areas NEW YORK, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced the appointment of Rita Jain, M.D. as Chief Medical Officer. Dr. Jain brings over 20 years of drug development and biopharmaceutical

      1/12/21 5:00:00 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Immunovant Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Immunovant Sciences with a new price target

      Jefferies initiated coverage of Immunovant Sciences with a rating of Hold and set a new price target of $20.00

      3/3/25 7:24:04 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Sciences downgraded by Wolfe Research

      Wolfe Research downgraded Immunovant Sciences from Outperform to Peer Perform

      1/3/25 7:34:55 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James resumed coverage on Immunovant Sciences with a new price target

      Raymond James resumed coverage of Immunovant Sciences with a rating of Outperform and set a new price target of $36.00

      10/10/24 8:38:30 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer reiterated coverage on Immunovant Sciences with a new price target

      Oppenheimer reiterated coverage of Immunovant Sciences with a rating of Outperform and set a new price target of $53.00 from $47.00 previously

      10/9/24 7:44:33 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer initiated coverage on Immunovant Sciences with a new price target

      Oppenheimer initiated coverage of Immunovant Sciences with a rating of Outperform and set a new price target of $50.00

      3/28/24 7:43:25 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman initiated coverage on Immunovant Sciences with a new price target

      Goldman initiated coverage of Immunovant Sciences with a rating of Buy and set a new price target of $50.00

      3/13/24 7:36:35 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan initiated coverage on Immunovant Sciences with a new price target

      JP Morgan initiated coverage of Immunovant Sciences with a rating of Overweight and set a new price target of $51.00

      2/20/24 7:00:18 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wolfe Research initiated coverage on Immunovant Sciences with a new price target

      Wolfe Research initiated coverage of Immunovant Sciences with a rating of Outperform and set a new price target of $55.00

      2/15/24 6:28:13 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Immunovant Sciences with a new price target

      Deutsche Bank initiated coverage of Immunovant Sciences with a rating of Buy and set a new price target of $50.00

      12/12/23 7:54:29 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Sciences upgraded by UBS with a new price target

      UBS upgraded Immunovant Sciences from Neutral to Buy and set a new price target of $55.00 from $18.00 previously

      10/13/23 7:43:27 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Immunovant Inc. Financials

    Live finance-specific insights

    See more
    • Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast DetailsThe company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast

      3/18/25 4:32:00 PM ET
      $IMVT
      $ROIV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

      Lead asset IMVT-1402 rapidly progressing with now six Investigational New Drug (IND) applications cleared and pivotal studies in Graves' disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) now enrolling with 2.25ml autoinjector Additional results from batoclimab proof-of-concept study in GD, including 6-month treatment free remission data expected in summer 2025 Top line results of the batoclimab trial in myasthenia gravis (MG) and initial results from period 1 of batoclimab trial in chronic inflammatory demyelinating polyneuropathy (CIDP) expected by March 31, 2025 Pro forma cash balance of approximately $825 million as of December 31, 2024, including approximately $450 mil

      2/6/25 6:30:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

      Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves' disease (GD) demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs (ATDs); initiation of potentially registrational trial to evaluate IMVT-1402 in GD expected by year endIND cleared for IMVT-1402 in rheumatoid arthritis (RA), with potential best-in-class profile in difficult-to-treat (D2T) RA; initiation of potentially registrational trial to evaluate IMVT-1402 in D2T RA expected by March 31, 2025O

      11/7/24 6:30:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024

      Completed enrollment in batoclimab pivotal Myasthenia Gravis (MG) trial; top-line results and initiation of a potentially registrational program for IMVT-1402 on track for fiscal year end (March 31, 2025) Progressed development of lead asset IMVT-1402 with 3 Investigational New Drug (IND) applications expected to be active by calendar year end (December 31, 2024)Progressed Graves' disease (GD) program and on track to disclose additional results from the batoclimab study in GD as well as an overview of our development program for IMVT-1402 in GD in the fall of 2024As of June 30, 2024, Immunovant's cash and cash equivalents totaled approximately $560 million NEW YORK, Aug. 06, 2024 (GLOB

      8/6/24 4:05:00 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

      Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ending March 31, 2025Topline data from the batoclimab Myasthenia Gravis (MG) study is also expected over this fiscal year and further potentially registrational development in MG with IMVT-1402 is expected to begin in the same timeframeImmunovant has decided to run the batoclimab trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) longer prior to unblinding period 1 in order to better ensure that the data from the batoclimab trial, combi

      5/29/24 4:01:00 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

      Immunovant plans to initiate 4-5 potentially registrational programs for IMVT-1402 over the next fiscal year Immunovant plans to initiate trials in 10 indications for IMVT-1402 over the next two fiscal yearsInitial period 1 data from Phase 2b clinical trial of batoclimab in chronic inflammatory demyelinating polyneuropathy (CIDP) expected in the second or third quarter of calendar year 2024Global Phase 3 clinical trials of batoclimab in myasthenia gravis (MG) and thyroid eye disease (TED) progressing and on track for expected top-line data in the second half of calendar year 2024 (MG) and the first half of calendar year 2025 (TED) NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, In

      2/12/24 7:00:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

      Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402IMVT-1402 was observed to deliver dose dependent and deep IgG reductions similar to batoclimab in its Phase 1 studyIMVT-1402 600 mg was observed to deliver placebo-like impact on albumin and low-density lipoprotein cholesterol (LDL-C), similar to the previously disclosed 300 mg MAD cohort dataPotential best-in-class profile enables broad and exciting portfolio of indications, taking advantage of IgG reduction we expect will reach 80% with continued weekly dosing of 600 mg delivered by simple subcutaneous injection NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immu

      11/28/23 7:00:00 AM ET
      $IMVT
      $ROIV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

      Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402IMVT-1402 was observed to deliver dose dependent and deep IgG reductions similar to batoclimab in its Phase 1 studyIMVT-1402 600 mg was observed to deliver placebo-like impact on albumin and low-density lipoprotein cholesterol (LDL-C), similar to the previously disclosed 300 mg MAD cohort dataPotential best-in-class profile enables broad and exciting portfolio of indications, taking advantage of IgG reduction we expect will reach 80% with continued weekly dosing of 600 mg delivered by simple subcutaneous injection NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) --  Imm

      11/28/23 7:00:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

      IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimabNo decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (LDL-C) above baseline was observed after 4 weeks of dosing in the 300 mg multiple-ascending dose (MAD) SC cohortIMVT-1402 is being developed as a simple SC injection NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in I

      9/26/23 6:00:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

      IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimabNo decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (LDL-C) above baseline was observed after 4 weeks of dosing in the 300 mg multiple-ascending dose (MAD) SC cohortIMVT-1402 is being developed as a simple SC injection NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in

      9/26/23 6:00:00 AM ET
      $IMVT
      $ROIV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    Immunovant Inc. SEC Filings

    See more
    • SEC Form S-8 filed by Immunovant Inc.

      S-8 - Immunovant, Inc. (0001764013) (Filer)

      4/30/25 4:06:19 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Immunovant Inc.

      SCHEDULE 13D/A - Immunovant, Inc. (0001764013) (Subject)

      4/21/25 7:54:01 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Immunovant, Inc. (0001764013) (Filer)

      4/21/25 7:18:30 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Immunovant, Inc. (0001764013) (Filer)

      3/19/25 7:51:41 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Immunovant Inc.

      144 - Immunovant, Inc. (0001764013) (Subject)

      3/7/25 4:17:56 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Immunovant Inc.

      SCHEDULE 13G/A - Immunovant, Inc. (0001764013) (Subject)

      3/7/25 10:01:30 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Immunovant Inc.

      144 - Immunovant, Inc. (0001764013) (Subject)

      2/14/25 4:11:18 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Immunovant Inc.

      144 - Immunovant, Inc. (0001764013) (Subject)

      2/11/25 4:11:29 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Immunovant Inc.

      10-Q - Immunovant, Inc. (0001764013) (Filer)

      2/6/25 6:45:11 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Immunovant, Inc. (0001764013) (Filer)

      2/6/25 6:37:53 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care